We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+17.71%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.55B
AUM Growth
+$456M
Cap. Flow
+$316M
Cap. Flow %
20.36%
Top 10 Hldgs %
61.57%
Holding
33
New
7
Increased
11
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$121M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$78.6M
3
NVRO
NEVRO CORP.
NVRO
+$78.2M
4
EXEL icon
Exelixis
EXEL
+$66.4M
5
PCRX icon
Pacira BioSciences
PCRX
+$38.6M

Top Sells

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$104M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$54.2M
3
AMRN
Amarin Corp
AMRN
+$39.5M
4
DVAX
Dynavax Technologies
DVAX
+$32.9M
5
CORT icon
Corcept Therapeutics
CORT
+$9.74M

Sector Composition

Rank Sector Weight
1 Healthcare 99.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARX
26
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$14.5M 0.93%
1,454,761
– –
CSII
27
DELISTED
Cardiovascular Systems, Inc.
CSII
$9.87M 0.64%
305,235
-140,865
-32% -$3.88M
ANIP icon
28
ANI Pharmaceuticals
ANIP
$1.83B
$9.55M 0.62%
142,943
– –
FLXN
29
DELISTED
Flexion Therapeutics, Inc.
FLXN
$5.62M 0.36%
217,392
+10,000
+5% +$259K
DVAX
30
DELISTED
Dynavax Technologies
DVAX
– –
-1,658,795
Closed -$32.9M
IOVA icon
31
Iovance Biotherapeutics
IOVA
$2.09B
– –
-3,206,073
Closed -$54.2M
RDUS
32
DELISTED
Radius Health, Inc.
RDUS
– –
-2,900,893
Closed -$104M
CVRS
33
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
– –
-4,574,835
Closed -$6.27M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Consonance Capital Management held 33 positions worth $1.55B, up 42% from $1.09B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Consonance Capital Management deployed $316M of net new capital in Q2 2018, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Puma Biotechnology: 2,089,117 shares worth $124M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was Amarin Corp, an estimated $39.5M trimmed.

  • Consonance Capital Management's largest Q2 2018 buy was Puma Biotechnology: 2,089,117 shares worth $124M.
  • Consonance Capital Management added most to Pacira BioSciences in Q2 2018, an estimated $38.6M increase.
  • Consonance Capital Management's biggest Q2 2018 reduction was Amarin Corp, cutting an estimated $39.5M.
  • Consonance Capital Management fully exited Radius Health, Inc. in Q2 2018, selling an estimated $104M.
  • Consonance Capital Management's ten largest holdings make up 62% of its $1.55B portfolio in Q2 2018.
  • Consonance Capital Management opened 7 new positions and closed 4 in Q2 2018.
  • Consonance Capital Management's portfolio value rose 42% quarter-over-quarter to $1.55B.

Based on Consonance Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.